AssetMark Inc’s Enliven Therapeutics ELVN Stock Holding History

AssetMark Inc’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$57.5K	Buy	+1,255	New	+$68.4K	﹤0.01%	1829

Other funds holding ELVN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Highland Capital Management (Tennessee) Memphis, Tennessee $2.19B AUM 46.65% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

AssetMark Inc's ELVN Position: Q3 2026 in Review

AssetMark Inc opened a new position in Enliven Therapeutics (ELVN) in Q3 2026: 1,255 shares worth $57.5K. The stake represents ﹤0.01% of the portfolio and ranks #1829 among its holdings.

19 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

AssetMark Inc held 1,255 shares of Enliven Therapeutics worth $57.5K as of Q3 2026.
Enliven Therapeutics was a new AssetMark Inc position in Q3 2026.
Enliven Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1829 holding.
19 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.